Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2018-11-06
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in
different ways to stop the growth of cancer cells either by killing the cells or by stopping
them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune
system in different ways and stop cancer cells from growing. Giving azacitidine together with
lenalidomide and dexamethasone may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when
given together with lenalidomide and low-dose dexamethasone in treating patients with
relapsed or refractory multiple myeloma.